SCHEMBL19254750

SCHEMBL19254750

CCOc1ccc(-c2nc(C(N)=O)c3[nH]c(=O)n(C)c3n2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 7/20 0.55
CSNK2A2 P19784 1/20 0.54
CSNK2B P67870 1/20 0.54
KDM4E B2RXH2 4/20 0.52
RXFP1 Q9HBX9 3/20 0.52
USP2 O75604 3/20 0.52
TSHR P16473 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HSD17B10 Q99714 2/20 0.52
LMNA P02545 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
THRB P10828 1/20 0.49
NPSR1 Q6W5P4 2/20 0.47
HDAC3 O15379 3/20 0.47
HDAC4 P56524 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19207491 0.85 CSNK2A1 (0.49) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19254589 0.84 HDAC3 (0.49) CSNK2A1CSNK2A2CSNK2BKDM4EALDH1A1
SCHEMBL19254292 0.82 CSNK2A1 (0.67) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19207471 0.81 CSNK2A1 (0.69) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19254359 0.81 CSNK2A1 (0.67) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19207435 0.81 KDM4E (0.80) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL22400143 0.81 HSD17B10 (0.74) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL22400129 0.81 CSNK2A1 (0.79) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19254651 0.80 CSNK2A1 (0.64) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1
SCHEMBL19207493 0.80 CSNK2A1 (0.65) CSNK2A1CSNK2A2CSNK2BKDM4ERXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10765681-B2 Purine compounds possessing anticancer activity ACADEMIA SINICA (TW) 2020-09-08 US disclosed
WO-2017136689-A1 PURINE COMPOUNDS POSSESSING ANTICANCER ACTIVITY ACADEMIA SINICA (TW) 2017-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10765681-B2 Purine compounds possessing anticancer activity NTPCR, PNP, NUDT1 CSNK2A1 2675/4885CSNK2A2 2853/4885CSNK2B 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.